SCHEMBL4875132

SCHEMBL4875132

CC(C)(C)OC(=O)c1ccc(Nc2cnccn2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.49
NPC1 O15118 7/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
MAPT P10636 3/20 0.49
TP53 P04637 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
ABCG2 Q9UNQ0 1/20 0.46
KMT2A Q03164 5/20 0.44
KDM4E B2RXH2 4/20 0.44
POLB P06746 1/20 0.44
ROCK1 Q13464 1/20 0.44
NAMPT P43490 1/20 0.43
USP2 O75604 1/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
MEN1 O00255 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL647152 0.86 ROCK1 (0.58) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL4868677 0.82 ABCG2 (0.53) RAB9ANPC1SMN1; SMN2ABCG2ROCK1
SCHEMBL25469660 0.80 ABCG2 (0.52) MAPTABCG2KMT2AKDM4EPOLB
SCHEMBL16973166 0.79 BUB1 (0.47) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL4874678 0.78 AURKA (0.60) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL22970776 0.78 RAB9A (0.40) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL4872303 0.77 ABCG2 (0.50) RAB9ATP53ABCG2KMT2AKDM4E
SCHEMBL4872285 0.77 KMT2A (0.53) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL22970913 0.76 RAB9A (0.41) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL902713 0.76 CHEK1 (0.39) RAB9ANPC1SMN1; SMN2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076771-A1 Thrombopoietin Receptor Agonists REITER LAWRENCE A 2008-03-27 US disclosed
EP-1794156-A2 TROMBOPOIETIN RECEPTOR AGONISTS Pfizer Products Incorporated (US) 2007-06-13 EP disclosed
WO-2006033005-A2 THROMBOPOIETIN RECEPTOR AGONISTS PFIZER PRODUCTS INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076771-A1 Thrombopoietin Receptor Agonists MPL, THPO, TBXA2R RAB9A 2219/4885NPC1 4382/4885SMN1; SMN2 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.